Literature DB >> 27888154

Modulation of VEGF receptor 2 signaling by protein phosphatases.

Federico Corti1, Michael Simons2.   

Abstract

Phosphorylation of serines, threonines, and tyrosines is a central event in signal transduction cascades in eukaryotic cells. The phosphorylation state of any particular protein reflects a balance of activity between kinases and phosphatases. Kinase biology has been exhaustively studied and is reasonably well understood, however, much less is known about phosphatases. A large body of evidence now shows that protein phosphatases do not behave as indiscriminate signal terminators, but can function both as negative or positive regulators of specific signaling pathways. Genetic models have also shown that different protein phosphatases play precise biological roles in health and disease. Finally, genome sequencing has unveiled the existence of many protein phosphatases and associated regulatory subunits comparable in number to kinases. A wide variety of roles for protein phosphatase roles have been recently described in the context of cancer, diabetes, hereditary disorders and other diseases. In particular, there have been several recent advances in our understanding of phosphatases involved in regulation of vascular endothelial growth factor receptor 2 (VEGFR2) signaling. The receptor is the principal signaling molecule mediating a wide spectrum of VEGF signal and, thus, is of paramount significance in a wide variety of diseases ranging from cancer to cardiovascular to ophthalmic. This review focuses on the current knowledge about protein phosphatases' regulation of VEGFR2 signaling and how these enzymes can modulate its biological effects.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Blood vessels; Endothelial cells; Protein phosphatases; VEGFR2 signaling

Mesh:

Substances:

Year:  2016        PMID: 27888154      PMCID: PMC5205541          DOI: 10.1016/j.phrs.2016.11.022

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  266 in total

Review 1.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

Review 2.  PTP1B and TC-PTP: regulators of transformation and tumorigenesis.

Authors:  Matthew Stuible; Karen M Doody; Michel L Tremblay
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

3.  Molecular heterogeneity of tumor endothelium.

Authors:  William C Aird
Journal:  Cell Tissue Res       Date:  2008-08-23       Impact factor: 5.249

Review 4.  Signalling by protein phosphatases and drug development: a systems-centred view.

Authors:  Lan K Nguyen; David Matallanas; David R Croucher; Alexander von Kriegsheim; Boris N Kholodenko
Journal:  FEBS J       Date:  2012-03-14       Impact factor: 5.542

5.  Meeting Report Europhosphatase 2015: Phosphatases as Drug Targets in Cancer.

Authors:  Elmer Hoekstra; Maikel P Peppelenbosch; Gwenny M Fuhler
Journal:  Cancer Res       Date:  2016-01-07       Impact factor: 12.701

6.  NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells.

Authors:  Ehrin N Johnson; You Mie Lee; Tara L Sander; Elena Rabkin; Frederick J Schoen; Sunjay Kaushal; Joyce Bischoff
Journal:  J Biol Chem       Date:  2002-11-09       Impact factor: 5.157

7.  Vascular normalization in cerebral angiogenesis: friend or foe?

Authors:  Jisook Lee; Andrew Baird; Brian P Eliceiri
Journal:  Methods Mol Biol       Date:  2014

Review 8.  Current therapies and investigational drugs for peripheral arterial disease.

Authors:  Jun-Ichi Suzuki; Munehisa Shimamura; Hiroyuki Suda; Kouji Wakayama; Hidetoshi Kumagai; Yuichi Ikeda; Hiroshi Akazawa; Mitsuaki Isobe; Issei Komuro; Ryuichi Morishita
Journal:  Hypertens Res       Date:  2015-12-03       Impact factor: 3.872

9.  Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation.

Authors:  Toshiyuki Araki; Gordon Chan; Susan Newbigging; Lily Morikawa; Roderick T Bronson; Benjamin G Neel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-27       Impact factor: 11.205

10.  Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.

Authors:  Jung-Chen Su; Ai-Chung Mar; Szu-Hsien Wu; Wei-Tien Tai; Pei-Yi Chu; Chia-Yun Wu; Ling-Ming Tseng; Te-Chang Lee; Kuen-Feng Chen; Chun-Yu Liu; Hao-Chieh Chiu; Chung-Wai Shiau
Journal:  Sci Rep       Date:  2016-07-01       Impact factor: 4.379

View more
  17 in total

Review 1.  Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition.

Authors:  Rhian M Touyz; Ninian N Lang; Joerg Herrmann; Anton H van den Meiracker; A H Jan Danser
Journal:  Hypertension       Date:  2017-06-19       Impact factor: 10.190

2.  Knockdown of Cripto-1 inhibits the proliferation, migration, invasion, and angiogenesis in prostate carcinoma cells.

Authors:  Ding Wu; Zhan Shi; Hao Xu; Renfu Chen; Song Xue; Xiaoqing Sun
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

3.  Syndecan-2 selectively regulates VEGF-induced vascular permeability.

Authors:  F Corti; E Ristori; F Rivera-Molina; D Toomre; J Zhang; J Mihailovic; Z W Zhuang; M Simons
Journal:  Nat Cardiovasc Res       Date:  2022-05-16

4.  Suppressing VEGF-A/VEGFR-2 Signaling Contributes to the Anti-Angiogenic Effects of PPE8, a Novel Naphthoquinone-Based Compound.

Authors:  Ming-Jen Hsu; Han-Kun Chen; Jin-Cherng Lien; Yu-Han Huang; Shiu-Wen Huang
Journal:  Cells       Date:  2022-07-05       Impact factor: 7.666

5.  In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology.

Authors:  Arlinda Ljoki; Tanzila Aslam; Tina Friis; Ragnhild G Ohm; Gunnar Houen
Journal:  Int J Mol Sci       Date:  2022-04-12       Impact factor: 6.208

Review 6.  The Importance of NADPH Oxidases and Redox Signaling in Angiogenesis.

Authors:  Rodrigo Prieto-Bermejo; Angel Hernández-Hernández
Journal:  Antioxidants (Basel)       Date:  2017-05-13

7.  Bis(maltolato)oxovanadium(IV) Induces Angiogenesis via Phosphorylation of VEGFR2.

Authors:  Laura Parma; Hendrika A B Peters; Maria E Johansson; Saray Gutiérrez; Henk Meijerink; Sjef de Kimpe; Margreet R de Vries; Paul H A Quax
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

8.  Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury.

Authors:  Karla B Neves; Francisco J Rios; Robert Jones; Thomas Ronald Jeffry Evans; Augusto C Montezano; Rhian M Touyz
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

9.  N-terminal syndecan-2 domain selectively enhances 6-O heparan sulfate chains sulfation and promotes VEGFA165-dependent neovascularization.

Authors:  Federico Corti; Yingdi Wang; John M Rhodes; Deepak Atri; Stephanie Archer-Hartmann; Jiasheng Zhang; Zhen W Zhuang; Dongying Chen; Tianyun Wang; Zhirui Wang; Parastoo Azadi; Michael Simons
Journal:  Nat Commun       Date:  2019-04-05       Impact factor: 14.919

10.  Tyrosine-Protein Phosphatase Non-receptor Type 9 (PTPN9) Negatively Regulates the Paracrine Vasoprotective Activity of Bone-Marrow Derived Pro-angiogenic Cells: Impact on Vascular Degeneration in Oxygen-Induced Retinopathy.

Authors:  Michel Desjarlais; Pakiza Ruknudin; Maëlle Wirth; Isabelle Lahaie; Rabah Dabouz; José Carlos Rivera; Tiffany Habelrih; Samy Omri; Pierre Hardy; Alain Rivard; Sylvain Chemtob
Journal:  Front Cell Dev Biol       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.